250 related articles for article (PubMed ID: 8038709)
1. The interleukin-1 receptor antagonist and its delivery by gene transfer.
Evans CH; Robbins PD
Receptor; 1994; 4(1):9-15. PubMed ID: 8038709
[TBL] [Abstract][Full Text] [Related]
2. Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist.
Smeets RL; Joosten LA; Arntz OJ; Bennink MB; Takahashi N; Carlsen H; Martin MU; van den Berg WB; van de Loo FA
Arthritis Rheum; 2005 Jul; 52(7):2202-11. PubMed ID: 15986350
[TBL] [Abstract][Full Text] [Related]
3. The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor.
Burger D; Chicheportiche R; Giri JG; Dayer JM
J Clin Invest; 1995 Jul; 96(1):38-41. PubMed ID: 7615809
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-1 receptor antagonism.
Nikolic-Paterson DJ; Lan HY; Atkins RC
Semin Nephrol; 1996 Nov; 16(6):583-90. PubMed ID: 9125803
[TBL] [Abstract][Full Text] [Related]
5. In vivo inhibition of localized bone resorption by human recombinant interleukin-1 receptor antagonist.
Chole RA; Faddis BT; Tinling SP
J Bone Miner Res; 1995 Feb; 10(2):281-4. PubMed ID: 7754808
[TBL] [Abstract][Full Text] [Related]
6. In vivo mucosal delivery of bioactive human interleukin 1 receptor antagonist produced by Streptococcus gordonii.
Ricci S; Macchia G; Ruggiero P; Maggi T; Bossù P; Xu L; Medaglini D; Tagliabue A; Hammarström L; Pozzi G; Boraschi D
BMC Biotechnol; 2003 Sep; 3():15. PubMed ID: 13129437
[TBL] [Abstract][Full Text] [Related]
7. Differential binding of human interleukin-1 (IL-1) receptor antagonist to natural and recombinant soluble and cellular IL-1 type I receptors.
Svenson M; Nedergaard S; Heegaard PM; Whisenand TD; Arend WP; Bendtzen K
Eur J Immunol; 1995 Oct; 25(10):2842-50. PubMed ID: 7589081
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of the inhibitory effects of interleukin-1 receptor antagonist following administration as a recombinant protein or by gene transfer.
Gouze JN; Gouze E; Palmer GD; Liew VS; Pascher A; Betz OB; Thornhill TS; Evans CH; Grodzinsky AJ; Ghivizzani SC
Arthritis Res Ther; 2003; 5(5):R301-9. PubMed ID: 12932294
[TBL] [Abstract][Full Text] [Related]
9. Protection against collagen-induced arthritis by intramuscular gene therapy with an expression plasmid for the interleukin-1 receptor antagonist.
Kim JM; Jeong JG; Ho SH; Hahn W; Park EJ; Kim S; Yu SS; Lee YW; Kim S
Gene Ther; 2003 Sep; 10(18):1543-50. PubMed ID: 12907945
[TBL] [Abstract][Full Text] [Related]
10. Adenoviral delivery of IL-1 receptor antagonist abrogates disease activity during the development of autoimmune arthritis in IL-1 receptor antagonist-deficient mice.
Hur W; Cho ML; Yoon SK; Kim SY; Ju JH; Jhun JY; Heo SB; Moon YM; Min SY; Park SH; Kim HY
Immunol Lett; 2006 Aug; 106(2):154-62. PubMed ID: 16793145
[TBL] [Abstract][Full Text] [Related]
11. Mouse IL-1 receptor antagonist isoforms: complementary DNA cloning and protein expression of intracellular isoform and tissue distribution of secreted and intracellular IL-1 receptor antagonist in vivo.
Gabay C; Porter B; Fantuzzi G; Arend WP
J Immunol; 1997 Dec; 159(12):5905-13. PubMed ID: 9550387
[TBL] [Abstract][Full Text] [Related]
12. Increased production of intracellular interleukin-1 receptor antagonist type I in the synovium of mice with collagen-induced arthritis: a possible role in the resolution of arthritis.
Gabay C; Marinova-Mutafchieva L; Williams RO; Gigley JP; Butler DM; Feldmann M; Arend WP
Arthritis Rheum; 2001 Feb; 44(2):451-62. PubMed ID: 11229477
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data.
Bendele A; McAbee T; Sennello G; Frazier J; Chlipala E; McCabe D
Arthritis Rheum; 1999 Mar; 42(3):498-506. PubMed ID: 10088773
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-1 receptor antagonist therapy and induction of anterior chamber-associated immune deviation-type tolerance after corneal transplantation.
Yamada J; Zhu SN; Streilein JW; Dana MR
Invest Ophthalmol Vis Sci; 2000 Dec; 41(13):4203-8. PubMed ID: 11095616
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory activity of IL-1 receptor antagonist depends on the balance between binding capacity for IL-1 receptor type 1 and IL-1 receptor type II.
Ruggiero P; Bossù P; Macchia G; Del Grosso E; Sabbatini V; Bertini R; Colagrande A; Bizzarri C; Maurizi G; Di Cioccio V; D'Andrea G; Di Giulio A; Frigerio F; Grifantini R; Grandi G; Tagliabue A; Boraschi D
J Immunol; 1997 Apr; 158(8):3881-7. PubMed ID: 9103457
[TBL] [Abstract][Full Text] [Related]
16. Cloning, heterologous expression and characterization of murine interleukin 1 receptor antagonist protein.
Shuck ME; Eessalu TE; Tracey DE; Bienkowski MJ
Eur J Immunol; 1991 Nov; 21(11):2775-80. PubMed ID: 1834470
[TBL] [Abstract][Full Text] [Related]
17. Anion binding and controlled aggregation of human interleukin-1 receptor antagonist.
Raibekas AA; Bures EJ; Siska CC; Kohno T; Latypov RF; Kerwin BA
Biochemistry; 2005 Jul; 44(29):9871-9. PubMed ID: 16026159
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-1 and interleukin-1 receptor antagonist.
Dinarello CA
Nutrition; 1995; 11(5 Suppl):492-4. PubMed ID: 8748206
[TBL] [Abstract][Full Text] [Related]
19. Technology evaluation: MFG-IRAP, University of Pittsburgh.
Baragi VM
Curr Opin Mol Ther; 2000 Apr; 2(2):216-20. PubMed ID: 11249645
[TBL] [Abstract][Full Text] [Related]
20. Reduction of inflammation by decreasing production of interleukin-1 or by specific receptor antagonism.
Dinarello CA
Int J Tissue React; 1992; 14(2):65-75. PubMed ID: 1399323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
